Merck immunotherapy fails to improve survival in head and neck cancer – Reuters
Telegraph.co.uk |
Merck immunotherapy fails to improve survival in head and neck cancer
Reuters (Reuters) – Merck & Co said on Monday that its Keytruda immunotherapy failed to extend survival in previously treated patients with advanced head and neck cancer more than the standard combination therapy in a late-stage trial. The drug, which blocks a … Merck Drug Shows No Life-Extending Benefit in Head-and-Neck Cancer |
